Kaposi's Sarcoma and its Management in AIDS Patients: Recommendations from a Scandinavian Study Group

References

• Zurrida S, Bartoli C, Nole F. Classic Kaposi's sarcoma: a review of 90 cases. J Dermatol 1992; 19: 548–552
   PubMedGoogle Scholar
• Stribling J, Wertzner S, Smith G V. Kaposi's sarcoma in renal allograft recipients. Cancer 1978; 42: 442–446
   PubMed Web of Science ®Google Scholar
• Myers B D, Kessler E, Levi D. Kaposi's sarcoma in kidney transplant recipients. Arch Intern Med 1974; 133: 307–310
   PubMed Web of Science ®Google Scholar
• Harwood A R. Kaposi's sarcoma in renal transplant patients. AIDS: The epidemic of Kaposi's sarcoma and opportunistic infections, A E Friedman-Kien, L J Lauberstein. Masson, New York 1984; 41–44
   Google Scholar
• Friedman-Kein A, Laubenstein L, Marmor M. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men – New York City and California. MMWR 1981; 30: 305–308
   PubMedGoogle Scholar
• Masur H, Michilis M A, Green J B. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestations of cellular immune dysfunction. N Engl J Med 1981; 305: 1431–1438
   PubMed Web of Science ®Google Scholar
• Lundgren J D, Melbye M, Pedersen C, Rosenberg P S, Gerstoft J. Changing patterns of Kaposi's sarcoma in Danish AIDS patients with complete follow-up. Am J Epidemiol 1995; 141: 652–658
   PubMedGoogle Scholar
• Hermans P, Lundgren J D, Sommereijns B. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS 1996; 10: 911–917
   PubMedGoogle Scholar
• Lifson A R, Darrow W W, Hessol N A. Kaposi's sarcoma in a cohort of homosexual and bisexual men. Am J Epidemiol 1990; 131: 221–231
   PubMed Web of Science ®Google Scholar
• Elford J, McDonald A, Kaldor J. Kaposi's sarcoma as a sexually transmissible infection: an analysis of Australian AIDS surveillance data. AIDS 1993; 7: 1667–1671
   PubMed Web of Science ®Google Scholar
• Kaldor J M, Tindall B, Williamson P, Elford J, Cooper D A. Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. J AIDS 1993; 6: 1145–1149
   PubMedGoogle Scholar
• Jacobson L P, Munoz A, Fox R. Incidence of Kaposi's sarcoma in a cohort of homosexual men infected with the human immunodeficiency virus type I. J AIDS 3 Suppl 1990; 1: S24–S31
   Google Scholar
• Rutherford G W, Payne S F, Lemp G F. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco. J AIDS 3 Suppl 1990; 1: S4–S7
   Google Scholar
• Schechter M T, Marion S A, Elmslie K D, Ricketts M N, Nault P, Archibald C P. Geographic and birth cohort associations of Kaposi's sarcoma among homosexual men in Canada. Am J Epidemiol 1991; 134: 485–488
   PubMedGoogle Scholar
• Beckstead J H, Wood G S, Fletcher V. Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am J Pathol 1985; 119: 294–300
   PubMed Web of Science ®Google Scholar
• Guarda L G, Silva E G, Ordonez N G, Smith J L. Factor VIII in Kaposi's sarcoma. Am J Clin Pathol 1981; 76: 197–200
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin M S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865–1869
   PubMed Web of Science ®Google Scholar
• Levy J A. A new human herpesvirus: KSHV or HHV-8?. Lancet 1995; 346: 786
   PubMedGoogle Scholar
• Moore P S, Chang Y. Detection of herpes-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995; 332: 1181–1185
   PubMed Web of Science ®Google Scholar
• Dupin N, Grandadam M, Calvez V. Herpes-like DNA sequences in patients with mediterranean Kaposi's sarcoma. Lancet 1995; 345: 761–762
   PubMed Web of Science ®Google Scholar
• Benfield T L, Lundgren J D. Detection of HHV-8 in patients with pulmonary KS. Scand J Infect Dis, (in press)
   Google Scholar
• Whitby D, Howard M R, Tenant-Flowers M. Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346: 799–802
   PubMed Web of Science ®Google Scholar
• Gao S-J, Kingsley L, Hoover D R. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335: 233–241
   PubMed Web of Science ®Google Scholar
• Renne R, Zhang W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (herpesvirus 8) in culture. Nature Medicine 1996; 2: 342–346
   PubMed Web of Science ®Google Scholar
• Ambroziak J A, Blackbourn D J, Herndier B G. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 1995; 268: 582–583
   PubMed Web of Science ®Google Scholar
• Vogel J, Hinrichs S H, Reynolds R K, Luciw P A, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335: 606–11
   PubMed Web of Science ®Google Scholar
• Ensoli B, Nakamura S, Salahuddin S Z. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989; 243: 223–226
   PubMed Web of Science ®Google Scholar
• Weindel K, Marme D, Weich H A. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun 1992; 189: 824–831
   PubMedGoogle Scholar
• Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips A N. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. AIDS 1996; 10: 1101–1105
   PubMed Web of Science ®Google Scholar
• Glesby M J, Hoover D R, Weng S, Graham N MH, Phair J P, Detels R, Ho M, Saah A J. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173: 1477–1480
   PubMedGoogle Scholar
• Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994; 26: 749–752
   PubMed Web of Science ®Google Scholar
• Beral V, Peterman T A, Berkelman R L, Jaffe H W. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?. Lancet 1990; 335: 123–8
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Darby S. Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 1992; 339: 632–563
   PubMed Web of Science ®Google Scholar
• Archibald C P, Schechter M T, Le T N, Craib K JP, Montaner J SG, O'Shaughnessy M V. Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiology 1992; 3: 203–209
   PubMedGoogle Scholar
• Yuan-Hu R, Shih J WK, Weiss S H. Mycoplasma penetrans infection in male homosexuals with AIDS: high seroprevalence and association with Kaposi's sarcoma. Clin Inf Dis 1993; 17: 724–729
   PubMedGoogle Scholar
• Fischl M A, Richman D D, Grieco M H. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–191
   PubMed Web of Science ®Google Scholar
• Decker C F, Masur H. Current status of prophylaxis for opportunistic infections in HIV-infected patients. AIDS 1994; 8: 11–20
   PubMed Web of Science ®Google Scholar
• Gottlieb G J, Ackerman A B. Kaposi's sarcoma: a text and atlas. Lea and Febiger, Philadelphia 1988
   Google Scholar
• Lundgren J D, Pedersen C, Clumeck N. Survival differences in European AIDS patients 1979 1989. BMJ 1994; 308: 1068–1073
   PubMed Web of Science ®Google Scholar
• LeBourgeois J P, Frikha H, Piedbois P, LePechoux C, Mattin L, Haddad E. Radiother Oncol 1994; 30: 263–266
   PubMedGoogle Scholar
• Nobler M P, Leddy M E, Huh S H. The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J Clin Oncol 1987; 5: 107–12
   PubMed Web of Science ®Google Scholar
• Brambilla L, Boneschi V, Beretta G, Finzi A F. Intralesional chemotherapy for Kaposi's sarcoma. Dermatologica 1984; 169: 150–155
   PubMedGoogle Scholar
• Sulis E, Floris C, Sulis M L. Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma. Eur J Cancer Clin Oncol 1989; 25: 759–761
   PubMedGoogle Scholar
• Dupuy J, Price M, Lynch G, Bruce S, Schwartz M. Intra-lesional interferon-alpha and zidovudine in epidemic Kaposi's sarcoma. J Am Acad Dermatol 1993; 28: 966–972
   PubMed Web of Science ®Google Scholar
• Volberding P A, Lagakos S W, Kock M A. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with less than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–949
   PubMed Web of Science ®Google Scholar
• Fischl M A, Richman D D, Hansen N. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled study. Ann Intern Med 1990; 112: 727–737
   PubMed Web of Science ®Google Scholar
• Cooper D A, Gatell J M, Kroon S. Zidovudine in persons with asymptomatic HIV infection and CD4 + cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297–303
   PubMed Web of Science ®Google Scholar
• Concorde Coordinating Committee. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871–881
   PubMed Web of Science ®Google Scholar
• Volberding P A, Lagakos S W, Grimes J M. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272: 437–442
   PubMed Web of Science ®Google Scholar
• Krown S E, Metroka C, Wernz J C. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. J Clin Oncol 1989; 7: 1201–1207
   PubMed Web of Science ®Google Scholar
• Groopman J E, Gottlieb M S, Goodman J. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 671–676
   PubMed Web of Science ®Google Scholar
• Kovacs J A, Deyton L, Davey R. Combined zidovudine and interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Ann Intern Med 1989; 111: 280–287
   PubMed Web of Science ®Google Scholar
• Krown S E, Gold J WM, Niedzwiecki D. Interferon-alpha with zidovudine: safety, tolerance and clinical and virological effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 812–821
   PubMed Web of Science ®Google Scholar
• De Witt R, Danner S A, Bakker P JM. Combined zidovudine and interferon alpha treatment in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1991; 229: 35–40
   PubMedGoogle Scholar
• Fischl M A, Uttamchandani R B, Resnick L. A phase I study of recombinant human interferon-alpha2a or human lymphoblastoid interferon-alphal and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J AIDS 1991; 4: 1–10
   PubMedGoogle Scholar
• Mauss S, Jablonowski H. Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma. J AIDS 1994; 10: 157–162
   Google Scholar
• Podzamczer D, Bolao F, Clotet B. Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1993; 233: 247–253
   PubMedGoogle Scholar
• Mintzer D M, Real F X, Jovino L, Krown S E. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the Acquired Immunodeficiency Syndrome. Ann Intern Med 1985; 102: 200–202
   PubMedGoogle Scholar
• Volberding P A, Abrams D I, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the Acquired Immunodeficiency Syndrome. Ann Intern Med 1985; 103: 335–338
   PubMed Web of Science ®Google Scholar
• Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in Acquired Immunodeficiency Syndrome with an alternating vincristine-vinblastine regimen. Cancer Treatment Reports 1986; 70: 1121–1122
   PubMedGoogle Scholar
• Lassoued K, Clauvel J-P, Katlama C. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bieomycin as a single agent. Cancer 1990; 66: 1869–1872
   PubMedGoogle Scholar
• Remick S C, Reddy M, Herman D. Continous infusion bleomycin in AIDS-related Kaposi's sarcoma. J Clin Oncol 1994; 12: 1130–1136
   PubMed Web of Science ®Google Scholar
• Gill P S, Rarick M, Bernstein-Singer M. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Oncol 1990; 13: 315–319
   PubMed Web of Science ®Google Scholar
• Laubenstein L J, Krigel R L, Odajnyk C M. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984; 2: 1115–1120
   PubMed Web of Science ®Google Scholar
• Gill P S, Miles S A, Mitsuyasu R T. Phase 1 AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1994; 8: 1695–1699
   PubMed Web of Science ®Google Scholar
• Gill P S, Rarick M, McCutchan J A. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991; 90: 427–433
   PubMed Web of Science ®Google Scholar
• Fischl M A, Krown S E, O'Boyle K P. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. J AIDS 1993; 6: 259–264
   PubMed Web of Science ®Google Scholar
• Forssen E A, Ross M E. Daunoxome (R) treatment of solid tumors; preclinical and clinical observations. J Liposome Res 1994; 4: 481–512
   Google Scholar
• Uthayakumar S, Bower M, Money-Kyrle J. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 1996; 10: 515–519
   PubMed Web of Science ®Google Scholar
• Gill P S, Wernz J, Scadden D T. Randomised phase III trial of liposomal daunorubicin versus doxorubivin. bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353–2364
   PubMed Web of Science ®Google Scholar
• Saville M W, Lietzau J, Pluda J M. Treatment of HIV-as-sociated Kaposi's sarcoma with paclitaxel. Lancet 1995; 346: 26–28
   PubMed Web of Science ®Google Scholar
• Lunardi-Iskandar Y, Bryant J L, Zeman R A. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995; 375: 64–68
   PubMed Web of Science ®Google Scholar
• Gill P S, Loureiro C, Bernstein-Singer M, Rarick M U, Sattler F, Levine A M. Clinical effect of glucocorticoids on Kaposi's sarcoma related to the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med 1989; 110: 937
   PubMedGoogle Scholar
• Lundgren J D, Benfield T L. Newer therapies for Pneumocystis carinii pneumonia. Clin Pulm Med 1996; 3: 304–313
   Google Scholar
• Bakker P J, Danner S A, tenNapel C H. Treatment of poor prognostic epidemic Kaposi's sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocytemonocyte colony stimulating factor (rhGM-CSF). Eur J Cancer 1995; 31 A: 188–192
   Google Scholar
• Scadden D T, Bering H A, Levine J D. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alpha and zidovudine treatment of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9: 802–808
   PubMed Web of Science ®Google Scholar